Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Imclone systems (IMCL) -- Ignore unavailable to you. Want to Upgrade?

To: 5,17,37,5,101,... who wrote (414)	3/12/1999 11:54:00 AM
From: Market Tracker	Respond to of 2515

Thanks for all your helpful posts and links. I am a biomed neophyte, and long IMCL, and just wanted to pass this report along to make sure everyone has seen it. <><><><><><><><> SAN FRANCISCO, March 9 /PRNewswire/ -- The following is being issued by Moors & Cabot Dakin Securities, a member of the National Association of Securities Dealers, CRD number 594: Moors & Cabot Dakin analyst Jim McCamant initiated coverage of ImClone Systems (Nasdaq: IMCL) today with a "buy" rating and a 12-month price target of $30 per share. Mr. McCamant believes that the Company is on the verge of significant progress in the commercialization of important new drugs for the treatment of head and neck cancer. The Company has also recently entered into a large international Phase III trial of a vaccine for the treatment of lung cancer. In addition, ImClone Systems is planning Phase I/II clinical trials for an anti-angiogenesis compound (blocking growth of tumors) during the second half of 1999. Based upon comparable valuations of other iotechnology companies and discounted future revenues and earnings, ImClone ystems could attain a market capitalization of more than $1 Billion by the year 2001. SOURCE Moors & Cabot, Inc. -0- 03/09/99 /CONTACT: Sam Skinner, Executive Vice President, West Coast Division of Moors & Cabot, Inc., 415-981-2114, or sskinner@dakn.com/ /Web site: dakn.com (IMCL)